Physiotherapy Use and Access-Barriers in Persons with Multiple Sclerosis

Elzebaith Kate*

Department of Neurology, University of Florida, USA

Corresponding Author*

Elzebaith Kate

Department of Neurology, University of Florida, USA,

E-mail: kateelzebaith@gmail.com

Received 10 March 2021; **Accepted** 17 March 2021; **Published** 24 March 2021

Abstract

Physiotherapy may aggravate the symptoms of Multiple Sclerosis. Physiotherapy accessibility and possible barriers in persons with MS are not very well known.

Introduction

Multiple sclerosis is a chronic degenerative and inflammatory disease of the central nervous system. This mainly occurs in early adulthood. Almost 2 million people are affected worldwide by this disease. Disease-Modifying treatments are very essential to minimize the damage and the loss and still, there is no specific treatment for multiple sclerosis. The drugs that better the clinical symptoms of Multiple Sclerosis are very rare. Therefore these symptoms should be managed with symptomatic forms of therapy like occupational and physical therapies. Physiotherapy is recommended for the treatment of multiple sclerosis symptoms. It improves the quality of life and maintains mobility and also physiotherapy reduces the gait-related problems and bladder problems will also be reduced. Besides, this physiotherapy may improve balance, reduce the pain (shoulder, neck, joint, and back pain), and reduces fatigue. It is not widely used in many countries. A very less percentage of people are reported to receive physiotherapy on a regular basis. They reported that physiotherapy access for MS is mostly delayed by mobility, fatigue, continence and transport issues, and the necessity of attendance.

Many people has received the treatment this may lead to some other condition like progressive multifocal leukoencephalopathy. This is a rare viral infection that targets the nerve cells and damages the brain. The cost of the treatment is also costly this is the waste of money. There will also be many side effects from the medication they are using for the disease that they haven't have.

Fingolimod's pharmacologic activity is targeted towards lymphocyte migration out of lymph nodes. This action is highly dependent on the engagement of a Gprotein-coupled receptor, S1P1, present on the surface of the lymphocytes.

The TRANSFORMS double-blind, double-dummy randomized controlled trial in adults demonstrated the superior effect of fingolimod as compared to IFNb.65 In patients who received fingolimod, adverse events included cardiac arrhythmias, macular edema, increased liver-enzymes, carcinoma , and herpes viral infections. One published retrospective review of pediatric MS patients treated with fingolimod demonstrated reduced relapse rate. No adverse side effects were reported but follow-up time was on average 8.6 months.66 A randomized double-dummy active comparator study of fingolimod to IFN-b-1a is currently underway.